

U.S. 09/778,187

**RECEIVED
CENTRAL FAX CENTER
FEB 26 2008**

Docket No. 2873-US-CIP

2. Listing of Claims

This listing of claims will replace all prior versions and listings of claims in the application:

1-21 (Canceled)

22. (Currently amended) An isolated polypeptide selected from the group consisting of:

- (a) a polypeptide comprising amino acids X_1 to X_2 as shown in SEQ ID NO: 2, wherein X_1 is 1 or 39 and X_2 is 374 or 442; and
- (b) a polypeptide comprising amino acids X_3 to X_4 as shown in SEQ ID NO: 4, wherein X_3 is 1 or 21 and X_4 is 356 or 423; and
- (c) ~~a polypeptide comprising a fragment of amino acids X_1 to X_2 in (a) or X_3 to X_4 in (b), wherein said fragment has 1 to 5 amino acids removed from either the amino or carboxy terminus of amino acids 39-374 of SEQ ID NO: 2 or amino acids 21-356 of SEQ ID NO: 4;~~

~~said isolated polypeptide being capable of binding to a LDCAM polypeptide of SEQ ID NO: 2 or SEQ ID NO: 4, a B7L-1 polypeptide of SEQ ID NO: 8 or SEQ ID NO: 10, or both.~~

23. (Currently amended) The isolated polypeptide according to Claim 22 comprising amino acids X_1 to X_2 as shown in SEQ ID NO: 2 ~~or a fragment of said amino acids, wherein X_1 is 1 or 39 and X_2 is 374 or 442, wherein said fragment has 1 to 5 amino acids removed from either the amino or carboxy terminus of amino acids 39-374 of SEQ ID NO: 2.~~

24. (Currently amended) The isolated polypeptide according to Claim 23 wherein X_1 is 39 and X_2 is 374.

25. (Currently amended) The isolated polypeptide according to Claim 23 wherein X_1 is 39 and X_2 is 442.

U.S. 09/778,187

Docket No. 2873-US-CIP

26. (Currently amended) The isolated polypeptide according to Claim 22 comprising amino acids X₃ to X₄ as shown in SEQ ID NO: 4 ~~or a fragment of said amino acids, wherein X₃ is 1 or 21 and X₄ is 356 or 423, wherein said fragment has 1 to 5 amino acids removed from either the amino or carboxy terminus of amino acids 21-356 of SEQ ID NO: 4.~~

27. (Currently amended) The isolated polypeptide according to Claim 26 wherein X₃ is 21 and X₄ is 356.

28. (Currently amended) The isolated polypeptide according to Claim 26 wherein X₃ is 21 and X₄ is 423.

29. (Previously presented) The isolated polypeptide according to Claim 23 or 26 that is soluble.

30. (Previously presented) A fusion polypeptide comprising the polypeptide according to Claim 22.

31. (Previously presented) The fusion polypeptide according to Claim 30, wherein said fusion polypeptide comprises a Fc region, or a peptide linker, or a Fc region and a peptide liker.

32. (Previously presented) An oligomer comprising the polypeptide according to Claim 22.

33. (Previously presented) The oligomer according to Claim 32 which is a dimer, a trimer, or a tetramer.

34. (Previously presented) A composition comprising the polypeptide according to Claim 22 and a suitable carrier.

35-63. (Cancelled)